In this national study of AAT augmentation therapy for lung transplant recipients with AAT deficiency, we found that only 109 of 447 recipients with AAT deficiency had evidence of outpatient AAT augmentation therapy pre-LT, and that younger recipients were more likely to have received augmentation therapy. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.